Clin Osteol 2026; 31(2): 84-86 | DOI: 10.36290/clo.2026.012

Tibolone and the bone healthMain theme

Tomáš Fait
Gynekologicko-porodnická klinika 2. LF UK a FNMH, Praha

Hormone replacement therapy is the most effective treatment for acute climacteric syndrome and prevention of chronic changes from estrogen deficiency. Tibolone as a selective regulator of tissue estrogenic activity is the only alternative of comparable efficacy with an excellent safety profile. It achieves better results in the area of influencing the psyche and sexuality of postmenopausal women and in some safety parameters (reduces mammographic density). Its effect on bone health is comparable to hormone replacement therapy.

Keywords: tibolone, menopause, osteoporosis.

Accepted: June 12, 2026; Published: July 1, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fait T. Tibolone and the bone health. Clinical Osteology. 2026;31(2):84-86. doi: 10.36290/clo.2026.012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 50 CZK
    will be unlocked 1.7.2027

    References

    1. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. Maturitas. 2005;51:21-8. Go to original source...
    2. Fait T, Žižka Z. Mammographic density - a risk factor for breast cancer. Prague Medical Report. 2007;108:205-14.
    3. Fait T. Tibolon - jediný zástupce skupiny STEARs. Cas Lek Ces. 2019;158:107-11.
    4. Rymer J; Robinson J; Fogelman I. 10 years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric. 2002;5:390-8. Go to original source...
    5. Roux C, Pelissier C, Fechtenbaum J, et al. Randomized, double-blind, 2-year comparison of tibolone with 17β-estradiol and Norethindrone acetate in preventing postmenopausal bone loss. Osteoporosis Int. 2002;13:241-8. Go to original source...
    6. Gallagher JC, Baylink DJ, Freeman R, et al. Prevention of bone loss with tibolone in postmenopausal women; results of two-randomised, double-blind, placebo-controlled, dose finding studies. J Clin Endocrinol Metab. 2001;86:4717-26. Go to original source... Go to PubMed...
    7. Berning B, Kuijk CV, Kuiper PM, et al. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone. 1996;19:395-9. Go to original source...
    8. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab. 1996;81:2419-22. Go to original source...
    9. Studd J, Arnala I, Kicovic PM, et al.: Tibolone increases bone mineral density in osteoporotic post-menopausal women in a randomized study. Obstet Gynecol. 1998,92:574-9. Go to original source...
    10. Lippuner K, Haenggi W, Birkhäuser MH, et al.: Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17 b-estradiol and dydrogesterone. J Bone Miner Res. 1997;12:806-12. Go to original source...
    11. Delmas PD, Davis SR, Hensen J, et al. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporos Int. 2008;19:1153-60. Go to original source...
    12. Cummings SR, Ettinger B, Delmas PD, et al. The effect of tibolone in older postmenopausal women. N Engl J Med. 2008;359:697-708. Go to original source...
    13. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double-blind randomised, non-inferiority trial. Lancet Oncol. 2009;10:135-46. Go to original source...
    14. Bots ML, Evans GW, Riley W, et al. The effect of tibolone and continuous combined CEE plus MPA on progression of CIM thickness. Eur Heart J. 2006;27:746-55. Go to original source...
    15. Langer RD, Landgren BM, Rymer J, et al. Effects of tibolone and continuous CEE/MPA on the endometrium and vaginal bleeding. AJOG. 2006;195:1320-7. Go to original source...
    16. Rymer J, Robinson J, Fogelman I. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Osteoporos Int. 2001;12(6):478-83. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.